NEW YORK, June 17 - DxS of Manchester, UK, said today that it has signed a license agreement for its Scorpions PCR-based genotyping technology with Minerva Biolabs of Berlin.
Minerva will use the fluorescence-based nucleic acid detection system in its development of a real-time PCR diagnostic test for the SARS virus. The molecular diagnostics firm has already developed Scorpions-based diagnostics for Legionella and Mycoplasma.
Steve Little, DxS CEO, said the company is "currently in discussion with a number of other international diagnostics companies with regards to technology licenses in addition to continuing to build our genotyping services business."
DxS said that Scorpions is also non-exclusively licensed to Ortho-Clinical Diagnostics in the field of oncology and to a number of oligonucleotide manufacturers.